pta20260310032
Public disclosure of inside information according to article 17 MAR
Schlagwоrt(e): Forecast / Full Year

Biofrontera AG: Financial Guidance for FY 2026

Leverkusen (pta032/10.03.2026/18:55 UTC+1)

The Management Board today provides the following financial guidance for fiscal year 2026:

  • Sales revenue: EUR 14 million –EUR 16 million
  • Adjusted EBITDA: EUR +3.5 million – EUR +5.1 million (unadjusted: EUR -0.5 million- EUR +0.5 million)

In 2026 Biofrontera expects sales revenues between EUR 14 and 16 million, (2025 adjusted sales revenues EUR 19 million, unadjusted sales revenues EUR 13 million). Adjusted and unadjusted sales revenues don't include the earn out from Biofrontera Inc, as earn out is a consideration from the business unit sale, not operational sales revenues. The earn out is based on the US-sales of Ameluz and is expected between EUR 3.5 million and 4.5 million in 2026 (2025: EUR 1.8 million).

Adjusted EBITDA for 2026 is expected to be between EUR 3.5 million and EUR 5.1 million (2025 adjusted EBITDA: EUR 4 million to 5 million, unadjusted EBITDA EUR -1.3 million to -0.8 million).

The company provides adjusted and unadjusted figures to allow an easier comparison of the business operations due to the following reasons: Following the sale of the U.S. business to Biofrontera Inc., IFRS accounting standards require the Company to classify the U.S. operations as discontinued operations. Accordingly, revenues, expenses, taxes and any cash inflows related to the disposed U.S. business, including potential earn-out payments, will not be included in reported sales revenue or EBITDA.

Instead, all results associated with the discontinued U.S. operations will be presented in the income statement as a single line item under "net result from discontinued operations", impacting net profit or loss.

(end)

Emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Contact Person: Investor Relations
Phone: +49 (0) 214 87 63 20
E-Mail: ir@biofrontera.com
Website: www.biofrontera.com
ISIN(s): DE000A4BGGM7 (Share)
Stock Exchange(s): Regulated Market in Dusseldorf, Frankfurt; Free Market in Munich, Stuttgart, Tradegate BSX
|